Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities

BMC Complementary and Alternative Medicine

Research Article

Oliver Dehus¹  Michael Schink¹ 

[1] Helixor Heilmittel GmbH, 72348, Rosenfeld, Germany;

关键词: Cancer;    Cytochrome P450;    Helixor®;    Interaction;    Mistletoe;    Viscum album;   

DOI  :  10.1186/s12906-017-2028-1

 received in 2017-08-23, accepted in 2017-11-24,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundEuropean mistletoe (Viscum album) products used in cancer therapy are frequently combined with other anti-cancer-drugs. Hence, potential herb-drug interactions have become a major safety concern in mistletoe therapy.MethodsThree European mistletoe products (Helixor® A, Helixor® M and Helixor® P from mistletoe grown on firs, apple trees and pines, respectively) were tested for inhibition of nine major cytochrome P450 (CYP) isoenzymes in a test system using pooled human liver microsomes and for induction of five CYP isoforms in human hepatocytes cultivated in vitro according to the relevant guideline.ResultsMajor inhibition did not occur in any of the CYP marker reactions. For some CYP isoenzymes, a minor or intermediate inhibition could be observed, but without dose effect relationship. Induction activity (≥ 1.5-fold increase) was not found with any of the three mistletoe products.ConclusionSince no induction capacity was found and major inhibition above 50% did not occur even with the highest concentration used, which is approximately 100,000-fold higher than the clinically relevant dose in plasma, a clinically relevant herb-drug interaction is not expected for Helixor® A, M, and P.

【 授权许可】

CC BY   
© The Author(s). 2017